U.S. flag

An official website of the United States government

NM_004360.5(CDH1):c.832+1G>A AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic/Likely pathogenic (4 submissions)
Last evaluated:
Nov 9, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000755032.15

Allele description [Variation Report for NM_004360.5(CDH1):c.832+1G>A]

NM_004360.5(CDH1):c.832+1G>A

Gene:
CDH1:cadherin 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
16q22.1
Genomic location:
Preferred name:
NM_004360.5(CDH1):c.832+1G>A
HGVS:
  • NC_000016.10:g.68810342G>A
  • NG_008021.1:g.78051G>A
  • NM_001317184.2:c.832+1G>A
  • NM_001317185.2:c.-784+1G>A
  • NM_001317186.2:c.-988+1G>A
  • NM_004360.5:c.832+1G>AMANE SELECT
  • LRG_301t1:c.832+1G>A
  • LRG_301:g.78051G>A
  • NC_000016.9:g.68844245G>A
  • NM_004360.3:c.832+1G>A
  • NM_004360.4:c.832+1G>A
  • NM_004360.5(CDH1):c.832+1G>AMANE SELECT
Links:
dbSNP: rs878854697
NCBI 1000 Genomes Browser:
rs878854697
Molecular consequence:
  • NM_001317184.2:c.832+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_001317185.2:c.-784+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_001317186.2:c.-988+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_004360.5:c.832+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
Observations:
1

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000882852Department of Molecular Diagnostics, Institute of Oncology Ljubljana
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Oct 24, 2018)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV001356969Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Oct 15, 2019)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002588960BRCAlab, Lund University
no assertion criteria provided
Pathogenic
(Aug 26, 2022)
germlineclinical testing

SCV002681995Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Nov 9, 2023)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing
not providedgermlineyesnot provided1not providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Department of Molecular Diagnostics, Institute of Oncology Ljubljana, SCV000882852.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV001356969.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant causes a G>A nucleotide substitution at the +1 position of intron 6 of the CDH1 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of CDH1 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Likely Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From BRCAlab, Lund University, SCV002588960.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot provided1not provided

From Ambry Genetics, SCV002681995.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The c.832+1G>A pathogenic intronic mutation results from a G to A substitution one nucleotide after coding exon 6 of the CDH1 gene. This nucleotide position is highly conserved in available vertebrate species. Another mutation at this position (c.832+1G>T) was reported in a 17-year-old patient with diffuse gastric cancer and history of cleft lip with cleft palate, and in a proband with a personal and family history of diffuse gastric cancer (Benusiglio PR et al. Int. J. Cancer 2013 May;132:2470; Ambry internal data). In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). In addition to the available clinical data, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024